• argenx announces U.S. Food and Drug Administration (FDA) approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

    Monday December 20th 2021

  • Early detection of Omicron facilitated with Emweb's Genome Detective

    Friday December 10th 2021

  • Biocartis’ Idylla™ SARS-CoV-2 testing successfully detects Omicron variant

    Thursday December 9th 2021

  • Spectacular results with Japanese encephalitis vaccine of ViroVet

    Wednesday December 8th 2021

  • New study demonstrates Idylla™ EGFR Mutation Test (CE-IVD) shortens time to patient management decisions for patients with non-small cell lung cancer

    Tuesday November 16th 2021

  • Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis

    Monday November 15th 2021

  • Precirix dosed first patients in Phase I/II clinical study evaluating CAM-H2 in HER2-positive metastatic cancer

    Wednesday October 6th 2021

  • Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease

    Monday October 4th 2021

  • Your news here?

  • Sequana Medical announces FDA approval to expand patient enrolment in North American pivotal alfapump® study (POSEIDON)

    Monday October 4th 2021

  • ExeVir announces first patient enrolled in phase 1b/2 clinical study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19

    Wednesday September 1st 2021

  • Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME in Ophthalmology Science

    Tuesday August 17th 2021


Strategic Partners